Efficacy and safety of ocrelizumab is maintained in patients with RRMS with suboptimal response to prior disease-modifying therapies: 4-year NEDA data from CASTING-LIBERTO

被引：0
作者：
Oreja-Guevara, C. [1 ]
Benedict, R. H. [2 ]
Comi, G. [3 ]
Cutter, G. [4 ]
Kister, I. [5 ]
Siva, A. [6 ]
Wiendl, H. [7 ]
Van Wijmeersch, B. [8 ]
Wuerfel, J. [9 ,10 ]
El Azzouzi, B. [11 ]
Buffels, R. [11 ]
Dirks, P. [11 ]
Kuenzel, T. [11 ]
Vermersch, P. [12 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] SUNY Buffalo, Dept Neurol, Jacobs Sch Med & Biomed Sci, Buffalo, NY USA
[3] Univ Vita Salute San Raffaele, Milan, Italy
[4] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL USA
[5] NYU, Langone Med Ctr, Multiple Sclerosis Comprehens Care Ctr, New York, NY USA
[6] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey
[7] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany
[8] Hasselt Univ, Univ MS Ctr, Hasselt, Belgium
[9] Univ Basel, Dept Biomed Engn, Med Image Anal Ctr MIAC AG, Basel, Switzerland
[10] Univ Magdeburg, Dept Neuroradiol, Magdeburg, Germany
[11] F Hoffmann La Roche Ltd, Basel, Switzerland
[12] Univ Lille, Inserm LilNCog U1172, CHU Lille, FHU Precise, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P289
引用
收藏
页码：327 / 329
页数：3
相关论文
共 35 条
  • [1] Efficacy and safety of ocrelizumab in patients with RRMS with suboptimal response to prior disease-modifying therapies: 3-year data from CASTING and LIBERTO 1-year interim results
    Van Wijmeersch, B.
    Comi, G.
    Oreja-Guevara, C.
    Wiendl, H.
    Wuerfel, J.
    Buffels, R.
    Dirks, P.
    Kuenzel, T.
    Kadner, K.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 543 - 544
  • [2] Fatigue and Other Patient-Reported Outcomes in Patients With RRMS who Switched to Ocrelizumab: 4-Year Data From CASTING-LIBERTO
    Kister, Ilya
    Benedict, Ralph
    Comi, Giancarlo
    Cutter, Gary
    Oreja Guevara, Celia
    Clinch, Susanne
    Kuenzel, Thomas
    Dirks, Petra
    Vermersch, Patrick
    NEUROLOGY, 2023, 100 (17)
  • [3] Safety of Ocrelizumab in Patients With RRMS With Suboptimal Response to Prior DMTs: Data From the CASTING Study
    Wiendl, H.
    Siva, A.
    Kadner, K.
    Kunzel, T.
    Buffels, R.
    Vermersch, P.
    Oreja-Guevara, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 119 - 119
  • [4] Ocrelizumab treatment in patients with rrms who had a suboptimal response with one or more prior disease-modifying therapies: chords 2-year results
    Weinstock-Guttman, B.
    Bermel, R.
    Cutter, G.
    Freedman, M.
    Leist, T.
    Pei, J.
    Kile, D.
    Musch, B.
    Reder, A.
    Wolinsky, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 225 - 226
  • [5] Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies
    Van Wijmeersch, B.
    Buffels, R.
    Clinch, S.
    Kuhelj, R.
    Wei, W.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 824 - 825
  • [6] Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts
    Wiendl, H.
    Comi, G.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wuerfel, J.
    Buffels, R.
    Kadner, K.
    Kuenzel, T.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 224 - 225
  • [7] Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)
    Vermersch, P.
    Eralinna, J.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Wei, W.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 32 - 32
  • [8] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
    Vermersch, P.
    Eralinna, J. -P.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Kuhelj, R.
    Wei, W.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 344 - 345
  • [9] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)
    Vermersch, P.
    Eralinna, J. P.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Kuhelj, R.
    Wei, W.
    Comi, G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [10] Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial
    Vermersch, Patrick
    Oreja-Guevara, Celia
    Siva, Aksel
    Van Wijmeersch, Bart
    Wiendl, Heinz
    Wuerfel, Jens
    Buffels, Regine
    Kadner, Karen
    Kuenzel, Thomas
    Comi, Giancarlo
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (03) : 790 - 801
1234